Lymphoma lymphocytic

Nodular sclerosis Hodgkin s lymphoma (grades 1 and 2) Lymphocyte-rich classical Hodgkin s lymphoma Mixed cellularity Hodgkin s lymphoma Lymphocyte depletion Hodgkin s lymphoma... 

Human non-Hodgkin s lymphoma lymphocytes 3.7 Monti et al., 1981b... 

Corticosteroid hormones are also useful anticancer agents because of their lymphotoxic effects. Their primary use is in management of hematologic mahgnancies, especially lymphomas, lymphocytic leukemias, and multiple myeloma. In addition to their cytotoxic effects, corticosteroids have many other applications in... 

Vincristine (1.4 to 2.0 mg/m ) is indicated in the treatment of acute leukemia and in combination therapy for Hodgkin s disease, non-Hodgkin s malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, and Wilm s tumor. In addition, vincristine has been used in the treatment of idiopathic thrombocytopenic purpura, Kaposi s sarcoma, breast cancer, and bladder cancer. The intrathecal administration of vincristine is fatal. 

USP (Oncovin) vindesine sulfate [59917-39 ] C43H55N5O7 -H2S0 852.01 (50) chil-dren lymphocytic leukemia Hodgkin s disease non-Hodg-kin s lymphomas Wilm s tumor neuroblastoma rhabdomyosarcoma, investigational dmg (paresthesias, foot drop, double vision, etc) constipation ileus alopecia leu-kopenia (occasional) ... 

Glucocorticoids have inhibitory (apoptotic) effects on lymphocyte proliferation and are used to treat leukemias and lymphomas. Estrogens (fosfestrol) are used to block the effect of androgens in prostate cancer. Progestogens (megestrol, medroxyprogesteroneacetate) have been useful for treating endometrial carcinoma, renal tumors, and breast cancer. 

Hodgkin s disease, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides, testicular cancer, Kaposi s sarcoma, breast cancer Acute leukemia, combination therapy for various cancers... 

Therapeutic efficacy of adoptively transferred cytotoxic T lymphocytes (CTL) has been demonstrated in clinical trials for cytomegalovirns (CMV)-associated disease (Walter et al. 1995), for EBV-associated lymphoma (Rooney et al. 1995) and nasopharyngeal carcinoma (Comoli et al. 2005) as well as for chronically active EBV infection (Savoldo et al. 2002). 

Epstein-Barr virus (EBV) Enveloped, icosahedral particles 150nm in diameter Infections occur by salivary exchange. In young children they are commonly asymptomatic but the virus persists in a latent form in lymphocytes. Infection delayed until adolescence often results in glandularfever. In tropical Africa, a severe EBV infection early in life predisposes the child to malignant facial tumours (Burkitt s lymphoma)... 

Teniposide, a topoisomerase II inhibitor, is administered as an infusion over 30 to 60 minutes to prevent hypotension. The pharmacokinetics are described by a three-compartment model, with an a half-life of 0.75 hours, a (5 half-life of 4 hours, and a terminal half-life of 20 hours. Considerable variability in clearance of teniposide in children has been reported.17 Teniposide has shown activity in the treatment of acute lymphocytic leukemia, neuroblastoma, and non-Hodgkin s lymphoma. Side effects include myelosuppression, nausea, vomiting, mucositis, and venous irritation. Hypersensitivity reactions may be life-threatening. 

Rituximab is a monoclonal antibody to the CD20 receptor expressed on the surface of B lymphocytes the presence of the antibody is determined during flow cytometry of the tumor cells. Cell death results from antibody-dependent cellular cytotoxicity. The pharmacokinetics of rituximab are best described by a two-compartment model, with a terminal half-life of 76 hours after the first infusion and a terminal half-life of 205 hours after the fourth dose.36 Rituximab has shown clinical activity in the treatment of B-cell lymphomas that are CD20+. Side effects include hypersensitivity reactions, hypotension, fevers, chills, rash, headache, and mild nausea and vomiting. 

This hot antibody is linked to radioactive iodine and binds to the CD20 receptor present on B lymphocytes (see Rituximab above). Tositumomab has shown activity in non-Hodgkin s lymphoma. Hematologic toxicity occurs several weeks after administration and may persist for months. Since radioactive iodine may have adverse effects on the thyroid, all patients must receive thyroid-blocking agents. 

The malignant lymphomas are hematologic cancers that consist of a cluster of diseases of the lymphoid tissue. The primary malignant cells for lymphomas are lymphocytes of B-cell, T-cell, and NK-cell origin. These cells originate from a small population of... 

Precursor B-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma Mature (peripheral) B-cell neoplasms B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma... 

Splenic marginal zone B-cell lymphoma ( villous lymphocytes)... 

Nodular lymphocyte-predominant Hodgkin s lymphoma Classical Hodgkin s lymphoma... 

Cancers Multiple myeloma Non-Hodgkin s lymphoma Hodgkin s disease Acute myeloid leukemia Neuroblastoma Germ cell tumors Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Myelodysplastic syndrome Myeloproliferative disorders Non-Hodgkin s lymphoma Hodgkin s disease Chronic lymphocytic leukemia Multiple myeloma... 

Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000 95 627-632. 

---